27 results about "Isoindole" patented technology

The present disclosure discloses a lurasidone hydrochloride oral film composition, preparation method and use thereof. The present disclosure discloses the lurasidone hydrochloride oral film composition including an active pharmaceutical, a film-forming material, a plasticizer and a flavoring agent, wherein the active pharmaceutical is (3aR,4S,7R,7aS)-2-((1R,2R)-2-[4-(1.2-benzisothiazol3-yl)piperazine-1-methyl]cyclohexylmethyl)hexahydro-4.7-methylene-2H-isoindole-1,3-dione hydrochloride denoted by the following formula I. The lurasidone hydrochloride oral film composition of the present disclosure has a good dissolution rate, a uniform appearance, a good flexibility, and a uniformity content meeting the requirement. Moreover, during the preparation process of the film liquid of the composition, sedimentation of the film will not occur. After the composition is dissolved in the user’s mouth, the user does not have any gritty feeling.

The invention discloses application of a metabonomics marker combination in preparation of a product for identifying benign and malignant lung ground glass nodules. The metabonomics marker combination comprises the following 11 metabonomics markers: 5 '-S-methyl-5'-thioadenosine, 5 '-S-methyl-4'-thioadenosine, 5 '-S-methyl-4'-thioadenosine, 5 '-S-methyl-4'-thioadenosine, 5 '-S-methyl-4'- And gamma-glutamylglutamic acid; the component A is N-stearoyl-D-red sphingosine; sphingosine; palmitoyl ethanolamide; 2-(4-(diethylamino) butyl-2-alkyne-1-yl) isoindene-1, 3-diketone is used as a raw material; vesenadine; zolpidem; the preparation method comprises the following steps: adding 4-hydroxyl-3-(2 '-hydroxyl-1, 1'-biphenyl-4-yl)-6-oxo-6, 7-dihydrothieno [2, 3-b] pyridine-5-formonitrile into a reaction kettle, and stirring for 20-30 minutes; and D-erythro-sphingosine; the invention relates to 3-methylpyrrole-2, 4-dicarboxylic acid. According to the invention, 11 specific metabolic markers closely related to benign and malignant lung ground glass nodules are found, the AUC value of a diagnosis model constructed on the basis of the 11 metabolic markers is up to 0.888, and the diagnosis model has extremely high identification accuracy and specificity.

The invention discloses a pyrazolo [5, 1-a] isoindole derivative as well as a synthesis method and application thereof, and belongs to the technical field of organic chemical synthesis. The invention solves the problems of harsh reaction conditions, limited substrate range and the like of continuous multi-step synthesis of a precursor in the existing pyrazolo [5, 1-a] isoindole compound synthesis process. According to the invention, a polarity reversal strategy is adopted, a cyano group is introduced into 1, 5-enyne to change the electronic characteristics of 1, 5-enyne, diazo, olefin and ethynyl benzene are reacted under mild conditions, two rings and three new chemical bonds are constructed through a series of intermolecular [3 + 2] cycloaddition, intramolecular cycloaddition and elimination reactions, and pyrazolo [5, 5-a]-1, 5-a-phenanthrene is efficiently synthesized. According to the present invention, the 1, 1-a] isoindole derivative has characteristics of good synthesis yield, simple operation of the synthesis method, easily available raw materials, good substrate universality and step economy, and provides the effective strategy for the drug design synthesis.

The invention discloses fluoroalkyl substituted azafluorene and pyridopyrimidino isoindole compounds as well as a synthesis method and application thereof, and belongs to the technical field of organic synthesis and drug discovery. The preparation method comprises the following steps: mixing a 3-alkenyl-1, 2, 4-oxadiazolone compound 1, a fluoroalkyl acetylenic ketone compound 2, a catalyst, an additive and an organic solvent, and carrying out heating reaction to prepare a fluoroalkyl substituted azafluorene compound 3 and / or a fluoroalkyl substituted pyridopyrimidino isoindole compound 4. Experimental research discovers that the compound disclosed by the invention has the activity of obviously inhibiting proliferation of Hela and HCT-116 cancer cells, so that the compound disclosed by the invention has obvious anti-cancer activity on cervical cancer and / or colon cancer, has potential medicinal value, and provides a new structural unit for drug screening.

The invention discloses a radionuclide-labeled isoindole-piperidinedione derivative and application thereof, and the structural formula of the radionuclide-labeled isoindole-piperidinedione derivative is shown in the specification. E3 ubiquitin ligase key protein CRBN is used as a new target for nuclear medicine molecular imaging research; dynamic expression of CRBN in a tumor microenvironment is accurately described by constructing a targeted molecular probe with an isoindole-piperidinedione parent nucleus structure, imaging guidance is provided for clinically and accurately screening benefited people and predicting the therapeutic effect of targeted CRBN, and imaging examples are also provided for researching dynamic expression of other key proteins in a ubiquitination system.

The present invention relates to an injectable form comprising: (i) At least 1.5 mg / mL of 2-[6-(4- cyclopropyl-4h-1,2,4-triazol-3-yl)-2-pyridyl]-5-morpholinocarbonyl-1-isoindolinone; (ii) a solvent selected from the group consisting of polyethylene glycol 300 (PEG300), polyethylene glycol 400 (PEG400), and mixtures thereof; and (iii) a co-solvent selected from the group consisting of PEG300, PEG400, propylene glycol, and mixtures thereof.

Substituted derivatives of 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol and their uses in pharmaceutical compositions for the treatment of central nervous system diseases or disorders are provided.

The present invention relates to 2,3-dihydro-1H-isoindol-1-one derivatives, their pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the voltage-gated sodium channel Nav1.1.

Substituted derivatives of 5-(4-chlorphenyl)-2, 3-dihydroimidazo [1, 2-b] isoindol-5-ol and their use in pharmaceutical compositions for the treatment of central nervous system diseases or disorders are provided.

Provided are a lurasidone hydrochloride orally dissolving film composition, a preparation method and application thereof. The lurasidone hydrochloride orally dissolving film composition comprises an active drug, a film forming material, a plasticizer and a flavoring agent, and the active drug is (3aR,4S,7R,7aS)-2-((1R,2R)-2-[4-(1.2-benzisothiazole 3-yl)piperazine-1-methyl]cyclohexylmethyl)hexahydro-4.7-methylen-2H-isoindole-1,3-dione hydrochloride salt as shown in formula I. The obtained lurasidone hydrochloride orally dissolving film composition has a good dissolution rate, does not have a sand feeling after dissolving in the oral cavity, has a uniform appearance, good flexibility, and does not have sedimentation during the preparation of the film liquid, and the content uniformity meets the requirements.

The application discloses a phenyl isoindolinone and zidovudine splicing compound and a preparation method and application thereof. The compound has potential biological activity, provides a compound source for biological activity screening, has important application value for drug screening and the pharmaceutical industry, and through in-vitro anti-tumor activity screening, it is found that the compound can selectively inhibit human lung cancer NCI-H1975 cells, and the selectivity index of the compound to normal cells BEAS-2B is high (the inhibition rate is only 12.51 %), the safety is about 7.2 times of that of osimertinib, and the compound exhibits good tumor cell selectivity and low potential side effects. In combination with the changes of NCI-H1975 cell mitochondrial ROS and membrane potential, it is indicated that the phenyl isoindolinone and zidovudine splicing compound derived from an EGFR allosteric inhibitor can play an anti-tumor role by affecting mitochondrial function.

The invention relates to the technical field of organic synthesis and the technical field of fine chemical engineering, in particular to an eight-membered ring parallel diisoindole heterocyclic hydrazone boron aza fused ring compound as well as a preparation method and application thereof. The structure of the eight-membered ring parallel diisoindole heterocyclic hydrazone boron aza fused ring compound is as shown in a formula (I). Wherein Ar is nitrogen-containing heterocyclic aryl, and R is selected from one of aryl, heterocyclic aryl and alkyl. According to the octatomic ring parallel diisoindole heterocyclic hydrazone boron nitrogen heterocyclic fused ring compound, the solubility, the molecular energy level and the photo-physicochemical properties of the compound are respectively regulated and controlled by regulating and controlling substituent groups on boron of a molecular skeleton, peripheral heteroatoms and fused ring modification, and a series of novel boron nitrogen full fused ring molecules are constructed. Meanwhile, the preparation method of the octatomic-ring parallel diisoindole heterocyclic hydrazone boron aza fused ring compound is simple and convenient, the reaction condition is mild, the raw materials are easy to obtain, the compound is easy to amplify for industrial preparation, and the compound has a wide application prospect.

The invention belongs to the field of organic synthesis medicines, and particularly discloses an isoindolone compound, a compound with a structure as shown in a formula (I) or a formula (II) or a formula (III) or pharmaceutically acceptable salt of the compound, or / and pharmaceutically acceptable salt of the isoindolone compound. The invention provides a series of isoindolone compounds which can be used as GPR139 receptor agonists, and proves that some embodiments of the series of isoindolone compounds can show good agonistic activity on GPR139 receptors, are remarkable in drug-likeness, have good medicinal potential for treating mental system diseases, are wide in market prospect, and can be used for preparing the GPR139 receptor agonists. The preparation method is simple and convenient, mild in reaction condition, convenient to operate and control, low in energy consumption, high in yield, low in cost and suitable for industrial production.

The application discloses a preparation method of a tetrahydrobenzo[f]isoindole compound. The tetrahydrobenzo[f]isoindole compound is prepared by taking 1,6-alkynyl compound as raw material, taking alkaline substance as additive, and performing a cyclization reaction in an organic solvent. The structural formula of the 1,6-alkynyl compound is R is one of phenyl, p-fluorophenyl, p-chlorophenyl, p-bromophenyl, p-tert-butylphenyl, p-benzophenyl, p-methoxyphenyl, p-trifluoromethylphenyl, m-chlorophenyl, m-methoxyphenyl, m-cyanophenyl, m-formylphenyl, 3,5-dimethoxyphenyl, o-methoxyphenyl, o-methylphenyl, 1-naphthyl, 2-thienyl, 3-thienyl and p-methylphenyl. The preparation method of the tetrahydrobenzo[f]isoindole compound is characterized by using cheap and easily obtained alkaline substance as additive, using green and low-toxicity solvent, simple and mild reaction condition, high regioselectivity and the ability to be used for the development of heterocyclic drug molecules.

The invention provides an isoindolone-containing CDK4 / 6 inhibitor and a preparation method and application thereof.The preparation method comprises the steps that ethyl bromoacetate is introduced to a piperazine group of a palbociclib structure to be hydrolyzed into acid, then amido bonds are generated to be linked with different isoindolone, and a series of compounds shown in the formula I are synthesized; the compound can be used for preventing or treating mammalian diseases related to abnormal expression of CDK4 / 6 and anti-tumor, anti-virus, antibacterial and anti-inflammatory related to CDK4 / 6. I.

The invention discloses an isoindole aggregation-induced emission molecule containing a phosphine oxide structure and a synthesis method of the isoindole aggregation-induced emission molecule, and belongs to the technical field of organic synthesis. O-propargyl alcohol benzaldehyde, arylamine and diaryl phosphine oxide are used as raw materials, the phosphine-containing isoindole derivative is efficiently synthesized under mild conditions through a one-pot cascade reaction, the method shows excellent atom economy and operation convenience, and it is found through substrate expansion research that the phosphine-containing isoindole derivative has a wide application prospect. The reaction has good compatibility to various functional groups, and steric hindrance and electronic effect have significant influence on reaction activity. Photophysical property characterization proves that the obtained phosphine-containing isoindole derivative has typical AIE characteristics, and the fluorescence intensity in an acetonitrile / water mixed solvent is remarkably enhanced along with the increase of the water content. Therefore, the invention not only provides a new thought for green synthesis of an isoindole skeleton, but also lays a foundation for application of the isoindole skeleton in the field of functional materials.

The application discloses application of a 1,6-diynyl compound as a mitochondrial fluorescent probe. The application discovers a new use of the 1,6-diynyl compound, and opens up a new application field. The benzisoindole dimer compound has different excitation wavelengths and emission wavelengths, and can meet the needs of different cell mitochondrial fluorescent probes. The benzisoindole dimer compound can be well positioned as a probe molecule. The benzisoindole dimer compound has good adaptability as a probe molecule in most microenvironments.

The application discloses a kind of containing isoindole ketone spleen tyrosine kinase inhibitor and its preparation method and application, belong to the technical field of medicinal chemistry.The application uses active group splicing method, retains the trimethoxy phenyl and pyrimidine of Fostamatinib structure as parent nucleus, replaces pyridoxylidene oxazinone with isoindole ketone, designs and synthesized 16 target compounds (general formula is shown below), and test the antitumor, antibacterial and anti-inflammatory activity of the compound, wherein, compound 6a is superior to positive control drug on the inhibition of human B lymphocyte (Raji), 6l on human breast cancer cell (MCF-7) and 6j human hepatoma cell (HepG2);Compound 6l has the best antibacterial activity, 6i and 6j are better than positive control drug Fostamatinib in anti-inflammatory activity, therefore, the isoindole ketone-containing spleen tyrosine kinase inhibitor of the application has good development prospect.

Disclosed are methods for constructing conjugates. An amine-containing component and a thiol-containing component, in comparable mole ratios, react with an ortho-phthalaldehyde in one step, to generate a conjugate bearing a substituted or an unsubstituted 1-thio-isoindole structure in the presence of an additive. The method provides a platform for the efficient and practical constructions of bioactive modular motifs.

The invention belongs to the field of organic synthesis and pesticide application, and particularly relates to application of a novel isoindolone substance, the structural formula is as follows: R1 is hydrogen, 3-methyl, 4-methyl, 4-methoxyl, 3-methoxyl or 2-methoxyl chloride; meanwhile, the N-methylbenzylamine can also be changed into N-methyl-N-(4-picolyl) amine (2) and N-methyl-2-thiophenemethylamine (3). Wherein R2 is selected from hydrogen, 3-methyl, 4-methyl, 5-methyl, 6-methyl, 3-methoxyl, 4-methoxyl, 5-methoxyl, 6-methoxyl, fluorine and chlorine; meanwhile, the 2-methoxy methyl benzoate can also be changed into the 2-methoxy methyl nicotinate pyridine (4). A biological activity determination result shows that the isoindolone compound containing the thiophene and methyl structure has medium to excellent inhibitory activity on phytophthora capsici, the activity of the compound A31 is the best, the inhibitory activity on the phytophthora capsici is 95 + / -3% and is equivalent to that of a control drug metalaxyl, and EC50 is equal to 1.3048 mu g / mL and is superior to that of the control drug metalaxyl.

This invention discloses a heterogeneous nanostructure photocatalyst, its preparation method, and its application. The invention modifies the surface of the g-C3N4 photocatalyst by introducing carbon quantum dots (CDs) through doping technology. The CDs / g-C3N4 composite photocatalyst abandons conventional metal catalysis, and its preparation process is simple, low-cost, and reusable without deactivation, making it a promising new composite photocatalyst in the field of visible light catalytic oxidation technology. Applying this catalyst to the visible light selective catalytic oxidation synthesis of the key intermediate 3-(4-nitro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione demonstrates good yields.

The invention discloses an isoindole-1-ketone derivative and an application of the isoindole-1-ketone derivative in preparation of an antiviral drug. The invention belongs to the technical field of medicine. The isoindole-1-ketone derivative has a structure as shown in a general formula I in the specification. The research finds that the isoindole-1-ketone derivative not only has obvious antiviral activity, but also has higher antiviral activity compared with the 6-site unsubstituted isoindole-1-ketone compound. The invention provides an effective technical means for antiviral treatment.

The present invention provides a therapeutic combination comprising (a) an isoindole-piperidine compound of formula (I) as described in the specification and (b) an alkylating agent temozolomide wherein the active ingredient is present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof; and the use of the therapeutic combination in the treatment of glioma.

The application belongs to the technical field of medicines, and particularly relates to a compound with inhibitory activity on DNA methyltransferase 1 (DNMT1) and a preparation method and application thereof. In the application, a DNMT1 small-molecule inhibitor with a 2-isoindole-3-carbazolyl propionic acid skeleton is found and prepared, and is expected to be applied to the treatment of diseases related to DNA hypermethylation, especially tumor treatment.

Provided are methods, compositions, uses, and products for combination therapy, including immunotherapy such as adoptive cell therapy, e.g., T cell therapy, and (S)-3-[4-(4-morpholin-4-ylmethylbenzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione, or its enantiomer or enantiomer mixture, or its pharmaceutically acceptable salt, solvate, hydrate, cocrystal, clathrate, or polymorph, for treating subjects with diseases or disorders, such as certain B-cell malignancies, as well as related methods, compositions, uses, and products.The cells generally express a recombinant receptor, such as a chimeric antigen receptor (CAR).In some embodiments, the disease or disorder is non-Hodgkin's lymphoma (NHL), for example, relapsed or refractory NHL, or a specific NHL subtype. TIFF2022554353000025.tif86128

The invention relates to the technical field of organic synthesis and the technical field of fine chemical engineering, in particular to an isoindole-diheterocyclic hydrazone triboron nitrogen fused ring compound and a preparation method and application thereof, and the structure of the isoindole-diheterocyclic hydrazone triboron nitrogen fused ring compound is shown as a formula I; wherein Ar is a nitrogen-containing heterocyclic aryl group, and R1, R2 and R3 are respectively and independently halogen atoms or aryl groups. Meanwhile, the invention also provides a one-pot three-component preparation method, a rigid isoindole diheterocyclic hydrazone ligand is constructed as a molecular scaffold, a coordination environment is organized in advance, and a three-core four-coordination boron-nitrogen condensed ring system with a clear structure is efficiently constructed by a one-step method. The emission wavelength of the isoindole-diheterocyclic hydrazone tri-boron-nitrogen fused ring compound is continuous and controllable, the solid-state luminescence property is excellent, the environmental stability and the thermal stability are excellent, and a new thought is provided for application of the isoindole-diheterocyclic hydrazone tri-boron-nitrogen fused ring compound in the fields of organic light-emitting diodes, organic solar cells, photoelectric detectors and the like.